Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) were widely used in advanced non-small cell lung cancers (NSCLCs) with EGFR sensitive mutation and greatly improved the patient survival. With the widespread use of EGFR TKI, TKI resistance is increasingly emerging in the clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yuan, Liu, Shuang, Jiang, Yanwen, Hua, Li, Wen, Linfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789526/
https://www.ncbi.nlm.nih.gov/pubmed/35106279
http://dx.doi.org/10.1016/j.rmcr.2022.101582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789526/
https://www.ncbi.nlm.nih.gov/pubmed/35106279
http://dx.doi.org/10.1016/j.rmcr.2022.101582

Ejemplares similares